EGFR-targeted Therapy for Gastric Cancer

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    38
  • sponsor
    National Cancer Center, Korea
Updated on 24 May 2021

Summary

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

Description

Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining

Details
Condition Gastric Adenocarcinoma, Adenocarcinoma of the Stomach, stomach adenocarcinoma
Treatment Anti-EGFR antibody in combination with weekly paclitaxel
Clinical Study IdentifierNCT04077255
SponsorNational Cancer Center, Korea
Last Modified on24 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically-proven gastric and gastroesophageal junction adenocarcinoma
Refractory to first-line chemotherapy for metastatic disease
Presence of at least 1 measurable lesion according to RECIST version 1.1
EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining

Exclusion Criteria

Prior exposure to taxane or EGFR-targeted therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note